BIOHIT OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.01 EUR | +0.50% |
|
0.00% | +6.63% |
| 04-15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
| 02-14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Office Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.63% | 32.71M | - | ||
| +9.94% | 8.32B | B- | ||
| -3.44% | 4.71B | B | ||
| -6.68% | 2.89B | - | ||
| +5.57% | 2.2B | - | ||
| -24.56% | 1.16B | - | ||
| -3.83% | 893M | C+ | ||
| -18.93% | 825M | - | ||
| -8.47% | 794M | - | ||
| -57.05% | 702M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOBV Stock
- Ratings Biohit Oyj
